PCL, Inc.

KOSDAQ 241820.KQ

PCL, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -1.39

PCL, Inc. Price to Earnings Ratio (P/E) is -1.39 on January 14, 2025, a 73.86% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

PCL, Inc. 52-week high Price to Earnings Ratio (P/E) is -1.36 on December 27, 2024, which is 2.49% above the current Price to Earnings Ratio (P/E).
PCL, Inc. 52-week low Price to Earnings Ratio (P/E) is -5.73 on January 17, 2024, which is -312.01% below the current Price to Earnings Ratio (P/E).
PCL, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -3.04.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

KOSDAQ: 241820.KQ

PCL, Inc.

CEO	Ms. Soyeon Kim
IPO Date	Feb. 23, 2017
Location	South Korea
Headquarters	Star valley, 99
Employees	31
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.

Key trends

Past 5 years